|
1
|
Amphetamine, past and present--a pharmacological and clinical perspective.
|
J Psychopharmacol
|
2013
|
1.22
|
|
2
|
Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders.
|
Br J Clin Pharmacol
|
2009
|
0.99
|
|
3
|
A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to D-amfetamine, methylphenidate and modafinil.
|
Neuropharmacology
|
2013
|
0.97
|
|
4
|
What is the prognosis for new centrally-acting anti-obesity drugs?
|
Neuropharmacology
|
2012
|
0.88
|
|
5
|
Metabolic consequences of antipsychotic therapy: preclinical and clinical perspectives on diabetes, diabetic ketoacidosis, and obesity.
|
Handb Exp Pharmacol
|
2012
|
0.82
|
|
6
|
Differences in the neurochemical and behavioural profiles of lisdexamfetamine methylphenidate and modafinil revealed by simultaneous dual-probe microdialysis and locomotor activity measurements in freely-moving rats.
|
J Psychopharmacol
|
2013
|
0.80
|
|
7
|
The 5-HT6 receptor as a target for developing novel antiobesity drugs.
|
Int Rev Neurobiol
|
2011
|
0.79
|